Dosimetric and Feasibility study of Sparing of Tubarial Salivary Glands inHead and Neck Cancer patients treated with Definitive Radiotherapy, with orwithout Concurrent Chemotherapy
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- 1. Primary endpoint: Dosimetry of Tubarial glands
研究概览
简要总结
Radiotherapy of head and neck cancer is known to cause Xerostomia as a long term side effect. Over the time from conventional 2D Radiotherapy to 3D CRT to IMRT, it has been seen that with advance in technology the incidence of radiation induced Xerostomia and the severity has been reduced to a great extent. Advanced technique RT in current practice has shown to reduce the dose to the salivary glands without compromising disease outcome. With the newly discovered tubarial salivary glands, this study will assess dosimetry of tubarial glands and effect of radiation on the glands in patients of head and neck cancer treated with radiotherapy with or without chemotherapy
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 90.00 Year(s)（—）
- 性别
- All
入选标准
- •WHO PS 0,1
- •Non-Nasopharyngeal and Non PNS/Nasal cavity Head and Neck Cancers
- •Definitive Radiotherapy.
- •For prospective study- patients with no overlap of the planning target volume (PTV) with tubarial glands will be considered.
排除标准
- •WHO PS >2
- •Nasopharyngeal tumors
- •PNS tumors
- •Post op HNC
- •Post NACT
- •If Treating RPLN
- •Post pharyngeal wall tumors
- •Oropharyngeal tumors extending into Nasopharynx.
结局指标
主要结局
1. Primary endpoint: Dosimetry of Tubarial glands
时间窗: PSMA PETCET at baseline and after 6 months of treatment completion ( only of prospective participants )
2. Secondary end point: Late Xerostomia, locoregional control
时间窗: PSMA PETCET at baseline and after 6 months of treatment completion ( only of prospective participants )
次要结局
- NA(NA)